The company has seven to nine directors and adopts a candidate nomination system. The term of office is three years. The shareholders will elect from the list of candidates, and they may be re-elected. The company elected the eighth board of directors (7 directors, including 4 independent directors) at the general meeting of shareholders in August 2021, with a term of office from August 20, 2021 to August 19, 2024. In order to establish a good governance system for the board of directors of the company, improve supervision functions and strengthen management functions, the “Rules of Procedures for the Board of Directors of Public Offering Companies” have been formulated for compliance.

Directors Biographies:

Chairman
Kuo, Hsien-Shou
Current Position(s):
  • Independent Director, TaiRx, Inc.
  • Honorary Professor, Taipei Medical University
Experience:
  • Representative juristic-person director, Oneness biotech Co., Ltd.
  • Professor, Taipei Medical University
  • Director, Ta-Cheng Tung Medical Research Foundation
Education:
  • PhD of Faculty of Pharmacy and Pharmaceutical Sciences, Meijo University, Japan

 

Director
Yang, Pan Chih
žCurrent Position(s):
  • Professor, Department of Internal Medicine, College of Medicine, National Taiwan University
  • Chairmen, Taiwan Bio-development Foundation
  • Academician and researcher jointly recruited by Institute of Biomedical Sciences, Academia Sinica
Experience:
  • President, National Taiwan University
  • Dean, College of Medicine, National Taiwan University
  • Vice dean, National Taiwan University Hospital
  • Director, Department of Internal Medicine, National Taiwan University Hospital
  • Director, National Center of Excellence for Clinical Trial and Research , National Taiwan University Hospital
  • Director, National Taiwan University Center of Genomic Medicine
Education:
  • M.D., College of Medicine, National Taiwan University
  • Ph.D., Graduate Institute of Clinical Medicine, National Taiwan University

 

Director Huang, Cheng Tsung
Current Position(s):

 

  • Supervisor, Hedonist Biochemical Technologies Co., Ltd.
Experience:
  • Chief Auditor, Chung-Shing Textile Co., Ltd.
  • Deputy General Manager of General Management Department, Wagon Group
Education:
  • Tamsui Institute of Business Administration

 

Director Tsai, Kao Chung
Current Position(s):

 

  • Chairman, Yiyou Management Consulting Co., Ltd.
  • Vice Chairman, Champion Microelectronic Corp.
  • Director, Glyconex Inc.
  • Independent Director, Holy Stone Healthcare Co., Ltd.
  • Independent Director, Sonix Technology Co., Ltd.
  • Independent Director, Double Bond Chemical Ind. Co., Ltd.
  • Member of the Remuneration Committee, Nien Hsing Textile Co., Ltd.
Experience:
  • Manager of Underwriting Department, Taiwan International Securities Co.,LTD.
  • Vice president of Underwriting Department, Barits Securities Corporation
  • General Manager, Yiyou Management Consulting Co., Ltd

 

 

 

 

 

 

 

Education:
  • Master of Department of Economics, Soochow University

 

Independent Director Lai, Yuan He
Current Position(s):
  • Honorary Professor, College of Law, National Chengchi University
  • Honorary Chair Professor, School of Law, Ming Chuan University
  • Executive Director, Taiwan Corporate Governance Association
  • Managing Supervisor, Taiwan Institute of Economic Research
Experience:
  • Dean, College of Law, National Chengchi University Director,
  • Chairman, Chilisin Electronics Corp.
  • Chairman, Teapo Electronic Corporation
  • Commissioner, Examination Yuan
  • Advisor and Vice Chairman of the Fair Trade Commission, Executive Yuan
  • Representative of the institutional supervisor, Kaimei Electronic Corp.
Education:
  • Bachelor of Laws, National Taiwan University
  • Juris Doctor, Kobe University, Japan
Independent Director
Han, Li Chun
Current Position(s):
  • Independent Director, StemCyte International Ltd.
  • Independent Director, Sinew Pharma Inc.
  • Remuneration Committee of CHO Pharma, Inc
Experience:
  • Deputy General Manager and Chief Supervisor of Brokerage Business, President Securities Corp
  • Chairman, President Futures Co., Ltd.
  • Chairman, President Capital Management Co.Ltd.
Education:
  • Department of Economics, National Chung Hsing University
Independent Director
Liang, Chi-Ming
Current Position(s):
  • Adjunct Chair Professor, College of Life Sciences, Kaohsiung Medical University
  • Visiting Chair Professor, Institute of Biomedical Sciences of Academia Sinica
  • Director, Taiwan Bio-development Foundation
  • Director, Asia Pacific Intellectual Property Association
  • Representative of institutional director, Yung Shin Pharmaceutical Industrial Co., Ltd.
Experience:
  • Director of Public Affairs and Special Assistant to the Dean, Academia Sinica
  • Director, Taiwan Biobank of Academia Sinica, Taiwan
  • Distinguished Research Fellow, Genomics Research Center, Academia Sinica, and CEO of BioHub Taiwan
Education:
  • Bachelor, Pharmacy, National Taiwan University
  • Master, Pharmacy, National Taiwan University
  • PhD. of Pharmacology, University of Arkansas for Medical Sciences
(note):Kingbird Tech Co., Ltd. reappointed Mr. Kuo, Hsien-Shou as the representative. And the BOD re-elected him as the chairperson of the board on December 20, 2021.

The implementation of diversity by board members

The company stipulates in the “Code of Practice on Corporate Governance” that the composition of the board of directors should be diversified. Except for directors who are also managers of the company, it is not advisable to exceed one-third of the number of directors, and it should formulate appropriate diversification policies based on its own operation, operation type and development needs.
The incumbent Board of Directors consists of seven directors, including four independent directors, except Chairman, Kuo, Hsien-Shou, who is concurrently the General Manager, none of whom are concurrently an executive officer of the Company.
It is mentioned in the Company’s “Code of Practice on Corporate Governance” that board members should generally possess the knowledge, skills and literacy necessary to perform their duties. In order to achieve the ideal goal of corporate governance, the overall board of directors should have the following capabilities:
  1. Operational judgment ability.
  2. Legal, Accounting and financial analysis capabilities.
  3. Operation and management capabilities.
  4. Crisis management capabilities.
  5. Industry knowledge.
  6. International market outlook.
  7. Leadership.
  8. Decision-making ability.
The Company nominates for and elects Board members through a candidate nomination system in compliance with the Company’s Articles of Incorporation. In addition to evaluating each candidate’s academic qualifications, we comply with the “Procedures for Election of Directors” and the “Corporate Governance Best Practice Principles” to ensure Board diversity and independence of Board members.

 

The implementation of Board diversity:

The Company elected new directors (including independent directors) at the 2021 annual general meeting. At present, there are seven directors on the Board, four of which are independent directors, accounting for 57.14% of all directors. The Company places emphasis on gender equality in the composition of the Board of Directors. All seven directors on the current Board of Directors are male, and female seats are expected to be added to the Board for the next term.

Results of the most recent annual board performance evaluation

 

According to our company’s “Self-Evaluation or Peer Evaluation of the Board of Directors”, an annual performance assessment is conducted based on the criteria and evaluation processes outlined in the procedures. This assessment encompasses the overall performance of the Board of Directors, individual board members, and functional committees.

 

Performance indicators

The measurement items of the performance evaluation of the company’s board of directors include the following five aspects:
  • Participation level in the management of the Company.
  • The decision-making quality of the Board.
  • Composition and structure of the Board of Directors.
  • Appointment of Director and continued education.
  • Internal control.
The measurement items of the performance evaluation of the board member performance (self-or peer-) include the following six aspects:
  • Mastery of the company objective and mission.
  • Understanding of directors’ duties.
  • Participation level in the management of the Company.
  • Engagement of internal relations and communication.
  • Directors’ professionalism and continued education.
  • Internal control.

The measurement items of the performance evaluation of the functional committees include the following five aspects:

  • Participation level in the management of the Company.
  • Comprehension of the responsibilities of the functional committee.
  • Enhancement of the decision-making quality of the functional committee.
  • Composition of functional committee and appointment of members.
  • Internal control.
The evaluation is conducted by the Finance Department through an internal questionnaire approach, comprising four sections related to the operation of the Board of Directors, director participation, the operations of the Remuneration Committee and the Audit Committee. This assessment includes evaluations by directors on the Board’s performance, self-assessment by directors regarding their own participation, and the company’s assessment of the functioning of the Audit Committee and Remuneration Committees.”

 

Performance results:

The performance evaluation of the board of directors in 2022 has been completed and the evaluation results already reported to the board of directors meeting and the Remuneration committee meeting on April 20, 2023.
The year 2022 board performance evaluation result was excellent including self-assessment results of the Board of Directors, Audit Committee, and Remuneration Committee. According to the evaluation results, the overall operation of the board of directors is still good.
In addition to the internal self-assessment conducted within the company, The company’s policy “Self-Evaluation or Peer Evaluation of the Board of Directors”, which clearly stipulates that the Company’s board performance evaluation shall be conducted by an external independent professional institution or a panel of external experts and scholars at least once every three years.. In 2020, the “Taiwan Institute of Ethical Business and Forensics” was appointed to perform the performance evaluation of the board of directors. For details, please refer to the following link:

 

In addition, the company has disclosed the “Self-Evaluation or Peer Evaluation of the Board of Directors” on the company website for inquiries.

Succession Plan: please refer to the following link:

Succession Plan PDF